tiprankstipranks
Trending News
More News >
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Advertisement

Catalyst Pharma (CPRX) Stock Statistics & Valuation Metrics

Compare
2,377 Followers

Total Valuation

Catalyst Pharma has a market cap or net worth of $2.52B. The enterprise value is $2.12B.
Market Cap$2.52B
Enterprise Value$2.12B

Share Statistics

Catalyst Pharma has 122,391,010 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding122,391,010
Owned by Insiders5.99%
Owned by Institutions16.61%

Financial Efficiency

Catalyst Pharma’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 20.22%.
Return on Equity (ROE)0.23
Return on Assets (ROA)0.19
Return on Invested Capital (ROIC)20.22%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee2.72M
Profits Per Employee905.46K
Employee Count181
Asset Turnover0.58
Inventory Turnover3.52

Valuation Ratios

The current PE Ratio of Catalyst Pharma is 12.5. Catalyst Pharma’s PEG ratio is ―.
PE Ratio12.5
PS Ratio
PB Ratio
Price to Fair Value3.40
Price to FCF
Price to Operating Cash Flow8.97
PEG Ratio

Income Statement

In the last 12 months, Catalyst Pharma had revenue of 491.73M and earned 163.89M in profits. Earnings per share was 1.38.
Revenue491.73M
Gross Profit422.89M
Operating Income195.12M
Pretax Income216.26M
Net Income163.89M
EBITDA232.90M
Earnings Per Share (EPS)1.38

Cash Flow

In the last 12 months, operating cash flow was 275.09M and capital expenditures -373.00K, giving a free cash flow of 274.72M billion.
Operating Cash Flow275.09M
Free Cash Flow274.72M
Free Cash Flow per Share2.24

Dividends & Yields

Catalyst Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.87
52-Week Price Change4.31%
50-Day Moving Average21.04
200-Day Moving Average22.36
Relative Strength Index (RSI)48.79
Average Volume (3m)1.37M

Important Dates

Catalyst Pharma upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Catalyst Pharma as a current ratio of 5.17, with Debt / Equity ratio of 0.30%
Current Ratio5.17
Quick Ratio5.01
Debt to Market Cap0.00
Net Debt to EBITDA-2.21
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Catalyst Pharma has paid 52.37M in taxes.
Income Tax52.37M
Effective Tax Rate0.24

Enterprise Valuation

Catalyst Pharma EV to EBITDA ratio is 8.41, with an EV/FCF ratio of 8.18.
EV to Sales3.98
EV to EBITDA8.41
EV to Free Cash Flow8.18
EV to Operating Cash Flow8.16

Balance Sheet

Catalyst Pharma has $652.80M in cash and marketable securities with $2.99M in debt, giving a net cash position of -$649.81M billion.
Cash & Marketable Securities$652.80M
Total Debt$2.99M
Net Cash-$649.81M
Net Cash Per Share-$5.31
Tangible Book Value Per Share$4.82

Margins

Gross margin is 63.22%, with operating margin of 39.68%, and net profit margin of 33.33%.
Gross Margin63.22%
Operating Margin39.68%
Pretax Margin43.98%
Net Profit Margin33.33%
EBITDA Margin47.36%
EBIT Margin39.68%

Analyst Forecast

The average price target for Catalyst Pharma is $33.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.00
Price Target Upside60.27% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast28.55%
EPS Growth Forecast196.96%

Scores

Smart Score6
AI Score81
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis